X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $11.25.

Several equities analysts have recently commented on XFOR shares. Wells Fargo & Company assumed coverage on X4 Pharmaceuticals in a research note on Friday, July 10th. They set an “overweight” rating and a $11.00 price target on the stock. Leerink Partners began coverage on shares of X4 Pharmaceuticals in a report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 target price on the stock. Finally, Weiss Ratings downgraded shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th.

X4 Pharmaceuticals Trading Down 2.1%

XFOR opened at $4.21 on Wednesday. The stock’s fifty day moving average is $4.07 and its two-hundred day moving average is $3.97. The company has a market capitalization of $417.42 million, a P/E ratio of -3.51 and a beta of 0.37. X4 Pharmaceuticals has a 52 week low of $2.45 and a 52 week high of $4.83. The company has a quick ratio of 11.02, a current ratio of 11.30 and a debt-to-equity ratio of 0.49.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Friday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%.The business had revenue of $8.81 million during the quarter, compared to analysts’ expectations of $2.42 million. Analysts forecast that X4 Pharmaceuticals will post -0.71 earnings per share for the current year.

Insider Activity

In related news, CFO David Kirske sold 8,543 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total value of $36,393.18. Following the completion of the transaction, the chief financial officer owned 167,750 shares of the company’s stock, valued at $714,615. The trade was a 4.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, President John Volpone sold 24,576 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $109,117.44. Following the sale, the president owned 265,305 shares of the company’s stock, valued at approximately $1,177,954.20. This represents a 8.48% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 80,555 shares of company stock worth $356,126. Corporate insiders own 1.13% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Indivisible Partners bought a new position in shares of X4 Pharmaceuticals in the 4th quarter worth $40,000. Rhumbline Advisers grew its stake in X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares during the last quarter. SummitTX Capital L.P. purchased a new position in X4 Pharmaceuticals in the first quarter valued at about $46,000. Pettinga Financial Advisors LLC bought a new position in X4 Pharmaceuticals in the second quarter worth about $47,000. Finally, Two Sigma Investments LP purchased a new stake in shares of X4 Pharmaceuticals during the third quarter valued at about $47,000. 72.03% of the stock is owned by institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.